Hepatic osteodystrophy and fracture risk prediction using FRAX tool in Indian patients with cirrhosis
- PMID: 33102768
- PMCID: PMC7578334
- DOI: 10.1002/jgh3.12369
Hepatic osteodystrophy and fracture risk prediction using FRAX tool in Indian patients with cirrhosis
Abstract
Background and aim: The main clinical relevance of hepatic osteodystrophy is the increased risk of fractures. Dual-energy X ray absorptiometry (DEXA)-based assessment of bone mineral density, the current gold standard for diagnosing osteoporosis, is not the sole determinant of fracture risk. Other clinical risk factors also play an important role. This study was carried out to assess the prevalence and risk factors of hepatic osteodystrophy and estimate the entailed fracture risk by using the FRAX tool in a cohort of Indian cirrhotics.
Methods: Consecutive patients with cirrhosis (n = 120) were recruited. Etiologic workup, liver function tests, serum calcium, phosphate, 25(OH)D, HbA1c, and DEXA scan were performed. Hepatic osteodystrophy was defined as a T score of < -1. FRAX scores were calculated using the Indian calculator.
Results: The study cohort was predominantly male (86.7%) with a median age of 49 (40-65) years. Alcohol was the most common etiology (80%). All patients had Child-Turcotte-Pugh class B (63.3%) or class B (36.7%) cirrhosis. Hepatic osteodystrophy was present in 83.3% patients. On multivariate analysis, smoking (odds ratio [OR]: 3.1 [1.76-4.7], P < 0.001) and serum 25(OH)D (OR: 0.23 [0.09-0.94]; P = 0.03) showed significant association with hepatic osteodystrophy. The 10-year probability of major osteoporotic fracture and hip fracture was 5.7% (2.1-28.9) and 2.5% (1.4-7.4), respectively. Using a FRAX probability cut-off of 20% for major osteoporotic fracture and 3% for hip fracture, 30% patients qualified for osteoporosis treatment.
Conclusion: Hepatic osteodystrophy is widely prevalent among Indian patients with cirrhosis and entails a high risk of fractures. Approximately one-third of patients with cirrhosis need treatment to reduce the risk of osteoporotic fractures.
Keywords: FRAX; T score; bone mineral density; cirrhosis; dual‐energy X ray absorptiometry; fracture risk; hepatic osteodystrophy; metabolic bone disease; osteoporosis; vitamin D.
© 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Hepatic osteodystrophy in cirrhosis due to alcohol-related liver disease.Rev Esp Enferm Dig. 2021 Aug;113(8):563-569. doi: 10.17235/reed.2020.7301/2020. Rev Esp Enferm Dig. 2021. PMID: 33267594
-
DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION.Endocr Pract. 2016 Apr;22(4):440-6. doi: 10.4158/EP15958.OR. Epub 2015 Dec 18. Endocr Pract. 2016. PMID: 26684149 Free PMC article.
-
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1. Ont Health Technol Assess Ser. 2006. PMID: 23074491 Free PMC article.
-
Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study.Osteoporos Int. 2013 Jan;24(1):179-86. doi: 10.1007/s00198-012-1920-2. Epub 2012 Mar 16. Osteoporos Int. 2013. PMID: 22422303 Review.
-
Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.J Clin Densitom. 2017 Jul-Sep;20(3):334-345. doi: 10.1016/j.jocd.2017.06.019. Epub 2017 Jul 19. J Clin Densitom. 2017. PMID: 28734710 Review.
Cited by
-
Investigation of the influential factors for hepatic osteodystrophy in chronic liver disease: A case-control survey among the patients attending a tertiary care hospital in a rural region of Northern India.Tzu Chi Med J. 2022 Jun 20;35(1):95-102. doi: 10.4103/tcmj.tcmj_27_22. eCollection 2023 Jan-Mar. Tzu Chi Med J. 2022. PMID: 36866351 Free PMC article.
-
Long Term Complications of Immunosuppression Post Liver Transplant.J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1103-1115. doi: 10.1016/j.jceh.2023.06.007. Epub 2023 Jun 23. J Clin Exp Hepatol. 2023. PMID: 37975039 Free PMC article.
-
Osteoporosis and Fragility Fractures in Patients with Liver Cirrhosis: Usefulness of FRAX® as a Screening Tool.J Clin Med. 2023 Dec 29;13(1):188. doi: 10.3390/jcm13010188. J Clin Med. 2023. PMID: 38202195 Free PMC article.
-
Clinical Usefulness of FRAX Score for Predicting Sarcopenia in Patients with Chronic Liver Disease.J Clin Med. 2021 Sep 9;10(18):4080. doi: 10.3390/jcm10184080. J Clin Med. 2021. PMID: 34575191 Free PMC article.
-
Caring for the Bone Health Among Liver Transplant Recipients.J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1130-1139. doi: 10.1016/j.jceh.2023.05.003. Epub 2023 May 12. J Clin Exp Hepatol. 2023. PMID: 37975037 Free PMC article. Review.
References
-
- Dempster DW, Lindsay R, Dempster L. Pathogenesis of osteoporosis. Lancet. 1993; 341: 797–801. - PubMed
-
- Hay JE. Osteoporosis in liver diseases and after liver transplantation. J. Hepatol. 2003; 38: 856–65. - PubMed
-
- Leslie W. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003; 125: 941–66. - PubMed
-
- Compston J, Cooper A, Cooper C et al Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62: 105–8. - PubMed
-
- Sachdev S, Bhasin RC, Kumari CK, Reys M. A study of metabolic bone disorder in cirrhosis liver. J. Assoc. Physicians India. 1976; 24: 5–11. - PubMed
LinkOut - more resources
Full Text Sources